Movatterモバイル変換


[0]ホーム

URL:


SG10201703242XA - Compositions and methods for inhibiting expression of transthyretin - Google Patents

Compositions and methods for inhibiting expression of transthyretin

Info

Publication number
SG10201703242XA
SG10201703242XASG10201703242XASG10201703242XASG10201703242XASG 10201703242X ASG10201703242X ASG 10201703242XASG 10201703242X ASG10201703242X ASG 10201703242XASG 10201703242X ASG10201703242X ASG 10201703242XASG 10201703242X ASG10201703242X ASG 10201703242XA
Authority
SG
Singapore
Prior art keywords
transthyretin
compositions
methods
inhibiting expression
inhibiting
Prior art date
Application number
SG10201703242XA
Inventor
Dinah Wen-Yee Sah
Gregory Hinkle
Rene Alvarez
Stuart Milstein
Qingmin Chen
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals IncfiledCriticalAlnylam Pharmaceuticals Inc
Publication of SG10201703242XApublicationCriticalpatent/SG10201703242XA/en

Links

Classifications

Landscapes

SG10201703242XA2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretinSG10201703242XA (en)

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
US10695608P2008-10-202008-10-20
US11573808P2008-11-182008-11-18
US15667009P2009-03-022009-03-02
US18554509P2009-06-092009-06-09
US24278309P2009-09-152009-09-15
US24479409P2009-09-222009-09-22

Publications (1)

Publication NumberPublication Date
SG10201703242XAtrue SG10201703242XA (en)2017-06-29

Family

ID=42062316

Family Applications (3)

Application NumberTitlePriority DateFiling Date
SG10201809460SASG10201809460SA (en)2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretin
SG10201703242XASG10201703242XA (en)2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretin
SG10201912276XASG10201912276XA (en)2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretin

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG10201809460SASG10201809460SA (en)2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretin

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG10201912276XASG10201912276XA (en)2008-10-202009-10-20Compositions and methods for inhibiting expression of transthyretin

Country Status (27)

CountryLink
US (8)US8168775B2 (en)
EP (4)EP3354733B1 (en)
JP (7)JP5791505B2 (en)
KR (6)KR101624869B1 (en)
CN (3)CN106834291B (en)
AU (1)AU2009307677C1 (en)
CA (3)CA2739895C (en)
CY (3)CY1116944T1 (en)
DK (2)DK2937418T3 (en)
EA (3)EA036772B1 (en)
ES (2)ES2656516T3 (en)
HR (2)HRP20150796T1 (en)
HU (3)HUE037875T2 (en)
IL (5)IL281434B2 (en)
LT (2)LT2937418T (en)
LU (1)LUC00098I2 (en)
MX (4)MX344354B (en)
NL (1)NL300965I2 (en)
NO (2)NO2937418T3 (en)
NZ (2)NZ602404A (en)
PL (2)PL2937418T3 (en)
PT (2)PT2344639E (en)
SG (3)SG10201809460SA (en)
SI (2)SI2344639T1 (en)
SM (2)SMT201800027T1 (en)
WO (1)WO2010048228A2 (en)
ZA (1)ZA201102876B (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9228186B2 (en)2002-11-142016-01-05Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
US20050244869A1 (en)*2004-04-052005-11-03Brown-Driver Vickie LModulation of transthyretin expression
CA2651839C (en)2006-05-112016-02-09Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of the pcsk9 gene
NZ588583A (en)2008-04-152012-08-31Protiva Biotherapeutics IncNovel lipid formulations for nucleic acid delivery
ES2656516T3 (en)2008-10-202018-02-27Alnylam Pharmaceuticals, Inc. Compositions and methods to inhibit the expression of transthyretin
CN105709229B (en)2008-11-102020-07-28阿布特斯生物制药公司 Novel lipids and compositions for delivery of therapeutic agents
CA2746514C (en)2008-12-102018-11-27Alnylam Pharmaceuticals, Inc.Gnaq targeted dsrna compositions and methods for inhibiting expression
AU2010208035B2 (en)*2009-01-292016-06-23Arbutus Biopharma CorporationImproved lipid formulation for the delivery of nucleic acids
KR102374518B1 (en)*2009-06-102022-03-16알닐람 파마슈티칼스 인코포레이티드Improved lipid formulation
WO2010148013A2 (en)*2009-06-152010-12-23Alnylam Pharmaceuticals, Inc.Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en)2009-06-152015-06-09Tekmira Pharmaceuticals CorporationMethods for increasing efficacy of lipid formulated siRNA
CA2767127A1 (en)2009-07-012011-01-06Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2464336A4 (en)*2009-08-142013-11-20Alnylam Pharmaceuticals IncLipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US9101643B2 (en)2009-11-032015-08-11Alnylam Pharmaceuticals, Inc.Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
US20230340473A1 (en)*2010-03-292023-10-26Alnylam Pharmaceuticals, Inc.Sirna therapy for transthyretin (ttr) related ocular amyloidosis
CA2792291A1 (en)*2010-03-292011-10-06Kumamoto UniversitySirna therapy for transthyretin (ttr) related ocular amyloidosis
SI2563920T1 (en)2010-04-292017-05-31Ionis Pharmaceuticals, Inc.Modulation of transthyretin expression
WO2011141705A1 (en)*2010-05-122011-11-17Protiva Biotherapeutics, Inc.Novel cationic lipids and methods of use thereof
WO2011153323A2 (en)*2010-06-022011-12-08Alnylam Pharmaceuticals, Inc.Compositions and methods directed to treating liver fibrosis
US9006417B2 (en)2010-06-302015-04-14Protiva Biotherapeutics, Inc.Non-liposomal systems for nucleic acid delivery
CA2813024A1 (en)2010-10-212012-04-26Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
BR122022001262B1 (en)2010-11-152022-09-27Life Technologies Corporation TRANSFECTION COMPOUNDS CONTAINING AMINE AND TRANSFECTION COMPLEX
WO2012079046A2 (en)*2010-12-102012-06-14Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2525223A1 (en)*2011-05-192012-11-21Universiteit MaastrichtIn vitro method for predicting in vivo genotoxicity of chemical compounds.
WO2012177906A1 (en)*2011-06-212012-12-27Alnylam Pharmaceuticals, Inc.Assays and methods for determining activity of a therapeutic agent in a subject
US9228188B2 (en)*2011-06-212016-01-05Alnylam Pharmaceuticals, Inc.Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
KR102232287B1 (en)2011-06-212021-03-29알닐람 파마슈티칼스 인코포레이티드Angiopoietin-like 3(angptl3) irna compostions and methods of use thereof
SMT202000308T1 (en)*2011-11-182020-07-08Alnylam Pharmaceuticals IncRnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
JP6305344B2 (en)2011-12-072018-04-04アルニラム・ファーマシューティカルズ・インコーポレーテッド Biodegradable lipids for delivery of active agents
US9035039B2 (en)*2011-12-222015-05-19Protiva Biotherapeutics, Inc.Compositions and methods for silencing SMAD4
SMT202200337T1 (en)*2012-11-262022-09-14Modernatx IncTerminally modified rna
IL293526A (en)2012-12-122022-08-01Harvard College Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
CA2897941A1 (en)2013-01-172014-07-24Moderna Therapeutics, Inc.Signal-sensor polynucleotides for the alteration of cellular phenotypes
US9790269B2 (en)2013-02-082017-10-17Misfolding Diagnostics, Inc.Transthyretin antibodies and uses thereof
EP4286517A3 (en)2013-04-042024-03-13President and Fellows of Harvard CollegeTherapeutic uses of genome editing with crispr/cas systems
BR112015027321A8 (en)*2013-05-012018-01-02Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
RU2716420C2 (en)2013-06-172020-03-11Те Брод Инститьют Инк.Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver
EP3019595A4 (en)2013-07-092016-11-30 THERAPEUTIC USES OF GENOME EDITING WITH CRISPR / CAS SYSTEMS
AR097738A1 (en)*2013-09-232016-04-13Alnylam Pharmaceuticals Inc METHODS TO TREAT OR PREVENT DISEASES ASSOCIATED WITH TRANSTIRETINE (TTR)
CN109536493A (en)*2013-10-022019-03-29阿尔尼拉姆医药品有限公司For inhibiting the composition and method of LECT2 gene expression
AU2014360314B2 (en)2013-12-062018-04-26Dicerna Pharmaceuticals, Inc.Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
AU2014362245A1 (en)2013-12-122016-06-16Massachusetts Institute Of TechnologyCompositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
CN105899658B (en)2013-12-122020-02-18布罗德研究所有限公司 Delivery, Use and Therapeutic Applications of CRISPR-CAS Systems and Compositions for HBV and Viral Diseases and Disorders
WO2015089486A2 (en)2013-12-122015-06-18The Broad Institute Inc.Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP4219699A1 (en)2013-12-122023-08-02The Broad Institute, Inc.Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015148580A2 (en)2014-03-252015-10-01Arcturus Therapeutics, Inc.Una oligomers having reduced off-target effects in gene silencing
US9856475B2 (en)2014-03-252018-01-02Arcturus Therapeutics, Inc.Formulations for treating amyloidosis
WO2015148582A1 (en)2014-03-252015-10-01Arcturus Therapeutics, Inc.Transthyretin allele selective una oligomers for gene silencing
KR102369736B1 (en)2014-05-012022-03-02아이오니스 파마수티컬즈, 인코포레이티드Compositions and methods for modulating complement factor b expression
HRP20221055T1 (en)2014-08-292022-12-23Alnylam Pharmaceuticals, Inc.Patisiran for use in treating transthyretin mediated amyloidosis
EP3215623A4 (en)2014-11-062018-09-26President and Fellows of Harvard CollegeCells lacking b2m surface expression and methods for allogeneic administration of such cells
EP3702456A1 (en)2014-12-242020-09-02The Broad Institute, Inc.Crispr having or associated with destabilization domains
EP3277289A4 (en)2015-04-012018-12-05Arcturus Therapeutics, Inc.Therapeutic una oligomers and uses thereof
MX2017012610A (en)2015-04-082018-03-16Alnylam Pharmaceuticals IncCompositions and methods for inhibiting expression of the lect2 gene.
EP3283631A1 (en)2015-04-132018-02-21Alnylam Pharmaceuticals, Inc.Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2016183041A2 (en)2015-05-082016-11-17President And Fellows Of Harvard CollegeUniversal donor stem cells and related methods
JP7107683B2 (en)2015-06-182022-07-27ザ・ブロード・インスティテュート・インコーポレイテッド CRISPR enzyme mutations that reduce off-target effects
WO2016205759A1 (en)2015-06-182016-12-22The Broad Institute Inc.Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
WO2017015671A1 (en)*2015-07-232017-01-26Arcturus Therapeutics, Inc.Compositions for treating amyloidosis
DK3329002T3 (en)2015-07-312021-01-11Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS FOR USING IT FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES
CA3011946A1 (en)2016-03-072017-09-14Arrowhead Pharmaceuticals, Inc.Targeting ligands for therapeutic compounds
SG10201912835QA (en)2016-09-022020-02-27Arrowhead Pharmaceuticals IncTargeting ligands
KR20190065341A (en)2016-10-062019-06-11아이오니스 파마수티컬즈, 인코포레이티드 Method of joining oligomeric compounds
AU2017368050A1 (en)2016-11-292019-06-20Puretech Lyt, Inc.Exosomes for delivery of therapeutic agents
JP7157752B2 (en)2017-02-172022-10-20エイドス セラピューティクス,インコーポレイティド Methods for the preparation of AG-10, intermediates thereof and salts thereof
AU2018336806B2 (en)2017-09-192025-04-10Alnylam Pharmaceuticals, Inc.Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
SG11202000771UA (en)2017-09-292020-04-29Regeneron PharmaNon-human animals comprising a humanized ttr locus and methods of use
BR112020005287A2 (en)2017-09-292020-09-24Intellia Therapeutics, Inc. compositions and methods for editing the ttr gene and treating attr amyloidosis
CN112218632A (en)*2018-03-232021-01-12文涵治疗有限公司Methods of treating TTR amyloidosis with AG10
MA53238A (en)2018-08-172022-04-13Eidos Therapeutics Inc AG10 FORMULAS
KR20210093232A (en)2018-10-092021-07-27더 유니버시티 오브 브리티시 콜롬비아 Compositions and systems and related methods comprising transfection competent vesicles free of organic solvent and detergent
WO2020128816A2 (en)2018-12-202020-06-25Pfizer Inc.Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
CA3137761A1 (en)2019-06-042020-12-10Regeneron Pharmaceuticals, Inc.Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
WO2021016075A1 (en)2019-07-192021-01-28Flagship Pioneering Innovations Vi, LlcRecombinase compositions and methods of use
WO2021041884A1 (en)2019-08-302021-03-04Alnylam Pharmaceuticals, Inc.Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
US12378560B2 (en)2019-10-292025-08-05Northwestern UniversitySequence multiplicity within spherical nucleic acids
JP2023500681A (en)*2019-11-062023-01-10アルニラム ファーマスーティカルズ インコーポレイテッド extrahepatic delivery
CA3174486A1 (en)2020-03-042021-09-10Flagship Pioneering Innovations Vi, LlcMethods and compositions for modulating a genome
WO2021178778A1 (en)2020-03-062021-09-10Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of transthyretin (ttr)
CN116322760A (en)2020-05-202023-06-23旗舰创业创新第六有限责任公司Coronavirus antigen composition and use thereof
AU2021275213A1 (en)2020-05-202023-02-02Flagship Pioneering Innovations Vi, LlcImmunogenic compositions and uses thereof
AU2021281453A1 (en)2020-05-292022-11-17Flagship Pioneering Innovations Vi, Llc.Trem compositions and methods relating thereto
IL298539A (en)2020-05-292023-01-01Flagship Pioneering Innovations Vi Llc trem compositions and methods related thereto
EP4208196A1 (en)2020-09-032023-07-12Flagship Pioneering Innovations VI, LLCImmunogenic compositions and uses thereof
CA3200234A1 (en)2020-11-252022-06-02Daryl C. DrummondLipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2022112919A1 (en)2020-11-252022-06-02Pfizer Inc.(aza)benzothiazolyl substituted pyrazole compounds
US20240175020A1 (en)2020-12-232024-05-30Flagship Pioneering Innovations Vi, LlcCompositions of modified trems and uses thereof
EP4294409A1 (en)*2021-02-222023-12-27Alnylam Pharmaceuticals, Inc.Folliculin irna compositions and methods thereof
WO2022187435A1 (en)2021-03-042022-09-09Alnylam Pharmaceuticals, Inc.Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4313109A1 (en)2021-03-312024-02-07Flagship Pioneering Innovations V, Inc.Thanotransmission polypeptides and their use in treating cancer
EP4334448A1 (en)2021-05-032024-03-13Alnylam Pharmaceuticals, Inc.Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
EP4351541A2 (en)2021-06-082024-04-17Alnylam Pharmaceuticals, Inc.Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
WO2023009547A1 (en)2021-07-262023-02-02Flagship Pioneering Innovations Vi, LlcTrem compositions and uses thereof
CN117795074A (en)*2021-08-032024-03-29阿尔尼拉姆医药品有限公司 Transthyretin (TTR) iRNA compositions and methods of use
MX2024002927A (en)2021-09-082024-05-29Flagship Pioneering Innovations Vi LlcMethods and compositions for modulating a genome.
CN118234867A (en)2021-09-172024-06-21旗舰创业创新六公司Compositions and methods for producing cyclic polyribonucleotides
KR20240126857A (en)2021-10-182024-08-21플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions and methods for purifying polyribonucleotides
CN114058636A (en)*2021-11-162022-02-18大连润生康泰医学检验实验室有限公司Method for cloning, expressing and purifying transthyretin gene
CA3238735A1 (en)2021-11-242023-06-01Jennifer A. NelsonImmunogenic compositions and their uses
JP2024541467A (en)2021-11-242024-11-08フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー Coronavirus immunogenic compositions and their uses
MX2024006407A (en)2021-11-242024-08-19Flagship Pioneering Innovations Vi LlcVaricella-zoster virus immunogen compositions and their uses.
JP2025500360A (en)2021-12-222025-01-09フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー Compositions and methods for purifying polyribonucleotides
TW202342064A (en)2021-12-232023-11-01美商旗艦先鋒創新有限責任公司Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023196634A2 (en)2022-04-082023-10-12Flagship Pioneering Innovations Vii, LlcVaccines and related methods
AU2023269030A1 (en)2022-05-092024-11-14Flagship Pioneering Innovations Vi, LlcTrem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en)2022-05-132023-11-16Flagship Pioneering Innovations Vii, LlcDouble stranded dna compositions and related methods
IL317109A (en)2022-05-252025-01-01Akagera Medicines IncLipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023250112A1 (en)2022-06-222023-12-28Flagship Pioneering Innovations Vi, LlcCompositions of modified trems and uses thereof
AU2023320333A1 (en)2022-08-012025-01-16Flagship Pioneering Innovations Vii, LlcImmunomodulatory proteins and related methods
WO2024035952A1 (en)2022-08-122024-02-15Remix Therapeutics Inc.Methods and compositions for modulating splicing at alternative splice sites
US20240174732A1 (en)2022-10-052024-05-30Flagship Pioneering Innovations V, Inc.Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
CN120513299A (en)2022-10-312025-08-19旗舰创业创新第六有限责任公司 Compositions and methods for purifying polyribonucleotides
WO2024098061A2 (en)2022-11-042024-05-10Genkardia Inc.Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
AR131008A1 (en)2022-11-082025-02-05Flagship Pioneering Innovations Vi Llc COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES
EP4619524A1 (en)2022-11-182025-09-24Genkardia Inc.Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
WO2024129874A1 (en)*2022-12-132024-06-20Sirnaomics, Inc.Products and compositions
WO2024129988A1 (en)2022-12-142024-06-20Flagship Pioneering Innovations Vii, LlcCompositions and methods for delivery of therapeutic agents to bone
WO2024151673A2 (en)2023-01-092024-07-18President And Fellows Of Harvard CollegeRecombinant nucleic acid molecules and their use in wound healing
WO2024151685A1 (en)2023-01-092024-07-18Beth Israel Deaconess Medical Center, Inc.Recombinant nucleic acid molecules and their use in wound healing
US20240269251A1 (en)2023-01-092024-08-15Flagship Pioneering Innovations V, Inc.Genetic switches and their use in treating cancer
WO2024173307A2 (en)2023-02-132024-08-22Flagship Pioneering Innovation Vii, LlcCleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
AU2024220221A1 (en)2023-02-172025-08-07Flagship Pioneering Innovations Vii, LlcDna compositions comprising modified cytosine
US20240285805A1 (en)2023-02-172024-08-29Flagship Pioneering Innovations Vii, LlcDna compositions comprising modified uracil
AU2024235803A1 (en)2023-03-152025-09-25Flagship Pioneering Innovations Vi, LlcCompositions comprising polyribonucleotides and uses thereof
WO2024192422A1 (en)2023-03-152024-09-19Flagship Pioneering Innovations Vi, LlcImmunogenic compositions and uses thereof
WO2024216128A1 (en)2023-04-122024-10-17Flagship Pioneering Innovations Vi, LlcTrems for use in correction of missense mutations
WO2025006684A1 (en)2023-06-282025-01-02Flagship Pioneering Innovations Vi, LlcCircular polyribonucleotides encoding antifusogenic polypeptides
WO2025042786A1 (en)2023-08-182025-02-27Flagship Pioneering Innovations Vi, LlcCompositions comprising circular polyribonucleotides and uses thereof
WO2025064475A2 (en)2023-09-182025-03-27Flagship Pioneering Innovations Vii, LlcIonizable lipidoid compositions and therapeutic uses thereof
WO2025098117A1 (en)*2023-11-062025-05-15成都倍特药业股份有限公司Rnai reagent and composition for inhibiting expression of transthyretin (ttr), and use
US20250162981A1 (en)2023-11-142025-05-22Flagship Pioneering Innovations Vii, LlcIonizable lipidoid compositions and therapeutic uses thereof

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US513030A (en)1894-01-16Machine for waxing or coating paper
US564562A (en)1896-07-21Joseph p
US3687808A (en)1969-08-141972-08-29Univ Leland Stanford JuniorSynthetic polynucleotides
US4522808A (en)1980-08-151985-06-11Societe Anonyme Dite: L'orealAnti-sunburn compositions containing 2-phenyl-indole derivatives
US4469863A (en)1980-11-121984-09-04Ts O Paul O PNonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4534899A (en)1981-07-201985-08-13Lipid Specialties, Inc.Synthetic phospholipid compounds
US4426330A (en)1981-07-201984-01-17Lipid Specialties, Inc.Synthetic phospholipid compounds
US5023243A (en)1981-10-231991-06-11Molecular Biosystems, Inc.Oligonucleotide therapeutic agent and method of making same
US4476301A (en)1982-04-291984-10-09Centre National De La Recherche ScientifiqueOligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (en)1982-08-091984-02-14Wakunaga Seiyaku KkOligonucleotide derivative and its preparation
FR2540122B1 (en)1983-01-271985-11-29Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en)1983-02-141986-08-12Wakunaga Seiyaku Kabushiki KaishaOligonucleotide derivatives
US4948882A (en)1983-02-221990-08-14Syngene, Inc.Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en)1983-03-101989-04-25Julian GordonSpecific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en)1983-09-011986-05-06The Johns Hopkins UniversityLinkage of proteins to nucleic acids
US5118800A (en)1983-12-201992-06-02California Institute Of TechnologyOligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en)1983-12-201992-06-02California Institute Of TechnologyDNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5550111A (en)1984-07-111996-08-27Temple University-Of The Commonwealth System Of Higher EducationDual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en)1984-07-191989-02-17Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5430136A (en)1984-10-161995-07-04Chiron CorporationOligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en)1984-10-161994-11-22Chiron CorporationOligonucleotides with selectably cleavable and/or abasic sites
US5258506A (en)1984-10-161993-11-02Chiron CorporationPhotolabile reagents for incorporation into oligonucleotide chains
US4828979A (en)1984-11-081989-05-09Life Technologies, Inc.Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (en)1985-01-081987-04-03Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5034506A (en)1985-03-151991-07-23Anti-Gene Development GroupUncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en)1989-12-201995-04-11Anti-Gene Development GroupSequence-specific binding polymers for duplex nucleic acids
US5235033A (en)1985-03-151993-08-10Anti-Gene Development GroupAlpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en)1989-12-201992-11-24Anti-Gene Development GroupSequence-specific binding polymers for duplex nucleic acids
US5185444A (en)1985-03-151993-02-09Anti-Gene Deveopment GroupUncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4762779A (en)1985-06-131988-08-09Amgen Inc.Compositions and methods for functionalizing nucleic acids
WO1987000201A1 (en)1985-07-051987-01-15Whitehead Institute For Biomedical ResearchEpithelial cells expressing foreign genetic material
US4980286A (en)1985-07-051990-12-25Whitehead Institute For Biomedical ResearchIn vivo introduction and expression of foreign genetic material in epithelial cells
US5139941A (en)1985-10-311992-08-18University Of Florida Research Foundation, Inc.AAV transduction vectors
US5317098A (en)1986-03-171994-05-31Hiroaki ShizuyaNon-radioisotope tagging of fragments
JPS638396A (en)1986-06-301988-01-14Wakunaga Pharmaceut Co LtdPoly-labeled oligonucleotide derivative
US4837028A (en)1986-12-241989-06-06Liposome Technology, Inc.Liposomes with enhanced circulation time
US4920016A (en)1986-12-241990-04-24Linear Technology, Inc.Liposomes with enhanced circulation time
US5264423A (en)1987-03-251993-11-23The United States Of America As Represented By The Department Of Health And Human ServicesInhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)1987-03-251994-01-04The United States Of America As Represented By The Department Of Health And Human ServicesInhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en)1987-06-111990-02-27Synthetic GeneticsNovel amphiphilic nucleic acid conjugates
EP0366685B1 (en)1987-06-241994-10-19Howard Florey Institute Of Experimental Physiology And MedicineNucleoside derivatives
EP0378576B1 (en)1987-09-111995-01-18Whitehead Institute For Biomedical ResearchTransduced fibroblasts and uses therefor
US5585481A (en)1987-09-211996-12-17Gen-Probe IncorporatedLinking reagents for nucleotide probes
US4924624A (en)1987-10-221990-05-15Temple University-Of The Commonwealth System Of Higher Education2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en)1987-10-221993-02-23Temple University Of The Commonwealth System Of Higher EducationEncapsulated 2',5'-phosphorothioate oligoadenylates
US5525465A (en)1987-10-281996-06-11Howard Florey Institute Of Experimental Physiology And MedicineOligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en)1987-11-121989-05-24Max Planck Gesellschaft MODIFIED OLIGONUCLEOTIDS
EP0391960B1 (en)1987-12-111994-08-17Whitehead Institute For Biomedical ResearchGenetic modification of endothelial cells
EP0400047B1 (en)1988-02-051997-04-23Whitehead Institute For Biomedical ResearchModified hepatocytes and uses therefor
US5082830A (en)1988-02-261992-01-21Enzo Biochem, Inc.End labeled nucleotide probe
JPH03503894A (en)1988-03-251991-08-29ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション Oligonucleotide N-alkylphosphoramidate
US5278302A (en)1988-05-261994-01-11University Patents, Inc.Polynucleotide phosphorodithioates
US5109124A (en)1988-06-011992-04-28Biogen, Inc.Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en)1988-06-061993-06-01Benner Steven AOligonucleotide analogs containing sulfur linkages
US5175273A (en)1988-07-011992-12-29Genentech, Inc.Nucleic acid intercalating agents
US5262536A (en)1988-09-151993-11-16E. I. Du Pont De Nemours And CompanyReagents for the preparation of 5'-tagged oligonucleotides
GB8824593D0 (en)1988-10-201988-11-23Royal Free Hosp School MedLiposomes
US5512439A (en)1988-11-211996-04-30Dynal AsOligonucleotide-linked magnetic particles and uses thereof
US5457183A (en)1989-03-061995-10-10Board Of Regents, The University Of Texas SystemHydroxylated texaphyrins
US5599923A (en)1989-03-061997-02-04Board Of Regents, University Of TxTexaphyrin metal complexes having improved functionalization
US5328470A (en)1989-03-311994-07-12The Regents Of The University Of MichiganTreatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5391723A (en)1989-05-311995-02-21Neorx CorporationOligonucleotide conjugates
US4958013A (en)1989-06-061990-09-18Northwestern UniversityCholesteryl modified oligonucleotides
US5451463A (en)1989-08-281995-09-19Clontech Laboratories, Inc.Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en)1989-08-291992-07-28Monsanto CompanyImproved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en)1989-09-121993-10-19Eastman Kodak CompanyOligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en)1989-09-151997-01-07Southern Research Institute2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
US5356633A (en)1989-10-201994-10-18Liposome Technology, Inc.Method of treatment of inflamed tissues
US5225212A (en)1989-10-201993-07-06Liposome Technology, Inc.Microreservoir liposome composition and method
US5399676A (en)1989-10-231995-03-21Gilead SciencesOligonucleotides with inverted polarity
DK0497875T3 (en)1989-10-242000-07-03Gilead Sciences Inc 2'-modified oligonucleotides
US5264564A (en)1989-10-241993-11-23Gilead SciencesOligonucleotide analogs with novel linkages
US5292873A (en)1989-11-291994-03-08The Research Foundation Of State University Of New YorkNucleic acids labeled with naphthoquinone probe
US5177198A (en)1989-11-301993-01-05University Of N.C. At Chapel HillProcess for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5486603A (en)1990-01-081996-01-23Gilead Sciences, Inc.Oligonucleotide having enhanced binding affinity
US5670633A (en)1990-01-111997-09-23Isis Pharmaceuticals, Inc.Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en)1991-10-151996-12-24Isis Pharmaceuticals, Inc.Oligonucleotides having phosphorothioate linkages of high chiral purity
US5578718A (en)1990-01-111996-11-26Isis Pharmaceuticals, Inc.Thiol-derivatized nucleosides
US5646265A (en)1990-01-111997-07-08Isis Pharmceuticals, Inc.Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en)1990-01-111995-10-17Isis Pharmaceuticals, Inc.N-2 substituted purines
US5587470A (en)1990-01-111996-12-24Isis Pharmaceuticals, Inc.3-deazapurines
US5681941A (en)1990-01-111997-10-28Isis Pharmaceuticals, Inc.Substituted purines and oligonucleotide cross-linking
WO1991013080A1 (en)1990-02-201991-09-05Gilead Sciences, Inc.Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en)1990-02-201993-05-25Gilead Sciences, Inc.Anthraquinone-derivatives oligonucleotides
US5321131A (en)1990-03-081994-06-14Hybridon, Inc.Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)1990-04-101995-11-28The Dupont Merck Pharmaceutical CompanyOligonucleotide analogs with sulfamate linkages
US5665710A (en)1990-04-301997-09-09Georgetown UniversityMethod of making liposomal oligodeoxynucleotide compositions
GB9009980D0 (en)1990-05-031990-06-27Amersham Int PlcPhosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (en)1990-05-111998-11-26Microprobe Corp., Bothell, Wash. Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US5608046A (en)1990-07-271997-03-04Isis Pharmaceuticals, Inc.Conjugated 4'-desmethyl nucleoside analog compounds
US5138045A (en)1990-07-271992-08-11Isis PharmaceuticalsPolyamine conjugated oligonucleotides
US5623070A (en)1990-07-271997-04-22Isis Pharmaceuticals, Inc.Heteroatomic oligonucleoside linkages
US5218105A (en)1990-07-271993-06-08Isis PharmaceuticalsPolyamine conjugated oligonucleotides
US5602240A (en)1990-07-271997-02-11Ciba Geigy Ag.Backbone modified oligonucleotide analogs
US5489677A (en)1990-07-271996-02-06Isis Pharmaceuticals, Inc.Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5618704A (en)1990-07-271997-04-08Isis Pharmacueticals, Inc.Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
EP0544824B1 (en)1990-07-271997-06-11Isis Pharmaceuticals, Inc.Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5610289A (en)1990-07-271997-03-11Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogues
US5541307A (en)1990-07-271996-07-30Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5677437A (en)1990-07-271997-10-14Isis Pharmaceuticals, Inc.Heteroatomic oligonucleoside linkages
US5688941A (en)1990-07-271997-11-18Isis Pharmaceuticals, Inc.Methods of making conjugated 4' desmethyl nucleoside analog compounds
ATE131827T1 (en)1990-08-031996-01-15Sterling Winthrop Inc COMPOUNDS AND METHODS FOR SUPPRESSING GENE EXPRESSION
US5245022A (en)1990-08-031993-09-14Sterling Drug, Inc.Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en)1990-08-281996-04-30Reed; Michael W.Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en)1990-09-121993-05-25Sterling Winthrop Inc.Process of linking nucleosides with a siloxane bridge
US5561225A (en)1990-09-191996-10-01Southern Research InstitutePolynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
AU662298B2 (en)1990-09-201995-08-31Gilead Sciences, Inc.Modified internucleoside linkages
US5432272A (en)1990-10-091995-07-11Benner; Steven A.Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU659824B2 (en)1990-10-311995-06-01Cell Genesys, Inc.Retroviral vectors useful for gene therapy
CA2095212A1 (en)1990-11-081992-05-09Sudhir AgrawalIncorporation of multiple reporter groups on synthetic oligonucleotides
GB9100304D0 (en)1991-01-081991-02-20Ici PlcCompound
JP3220180B2 (en)1991-05-232001-10-22三菱化学株式会社 Drug-containing protein-bound liposomes
US5539082A (en)1993-04-261996-07-23Nielsen; Peter E.Peptide nucleic acids
US5719262A (en)1993-11-221998-02-17Buchardt, Deceased; OlePeptide nucleic acids having amino acid side chains
US5714331A (en)1991-05-241998-02-03Buchardt, Deceased; OlePeptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5371241A (en)1991-07-191994-12-06Pharmacia P-L Biochemicals Inc.Fluorescein labelled phosphoramidites
US5571799A (en)1991-08-121996-11-05Basco, Ltd.(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (en)1991-10-171997-06-04Novartis AGBicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5594121A (en)1991-11-071997-01-14Gilead Sciences, Inc.Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5252479A (en)1991-11-081993-10-12Research Corporation Technologies, Inc.Safe vector for gene therapy
US5484908A (en)1991-11-261996-01-16Gilead Sciences, Inc.Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en)1991-12-131994-10-25Isis PharmaceuticalsCyclobutyl oligonucleotide surrogates
US5565552A (en)1992-01-211996-10-15Pharmacyclics, Inc.Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5595726A (en)1992-01-211997-01-21Pharmacyclics, Inc.Chromophore probe for detection of nucleic acid
FR2687679B1 (en)1992-02-051994-10-28Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
DE4203923A1 (en)1992-02-111993-08-12Henkel Kgaa METHOD FOR PRODUCING POLYCARBOXYLATES ON A POLYSACCHARIDE BASE
US5633360A (en)1992-04-141997-05-27Gilead Sciences, Inc.Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en)1992-06-011995-07-18Gilead Sciences, Inc.Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5587308A (en)1992-06-021996-12-24The United States Of America As Represented By The Department Of Health & Human ServicesModified adeno-associated virus vector capable of expression from a novel promoter
EP0577558A2 (en)1992-07-011994-01-05Ciba-Geigy AgCarbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5272250A (en)1992-07-101993-12-21Spielvogel Bernard FBoronated phosphoramidate compounds
US5478745A (en)1992-12-041995-12-26University Of PittsburghRecombinant viral vector system
US5574142A (en)1992-12-151996-11-12Microprobe CorporationPeptide linkers for improved oligonucleotide delivery
JP3351476B2 (en)1993-01-222002-11-25三菱化学株式会社 Phospholipid derivatives and liposomes containing the same
US5476925A (en)1993-02-011995-12-19Northwestern UniversityOligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5395619A (en)1993-03-031995-03-07Liposome Technology, Inc.Lipid-polymer conjugates and liposomes
GB9304618D0 (en)1993-03-061993-04-21Ciba Geigy AgChemical compounds
DE69404289T2 (en)1993-03-301998-02-19Sanofi Sa ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
WO1994022891A1 (en)1993-03-311994-10-13Sterling Winthrop Inc.Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (en)1993-04-101994-10-13Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US5502177A (en)1993-09-171996-03-26Gilead Sciences, Inc.Pyrimidine derivatives for labeled binding partners
CA2137297C (en)1993-12-062000-04-18Tsuyoshi MiyazakiReactive vesicle and functional substance-fixed vesicle
US5457187A (en)1993-12-081995-10-10Board Of Regents University Of NebraskaOligonucleotides containing 5-fluorouracil
US5446137B1 (en)1993-12-091998-10-06Behringwerke AgOligonucleotides containing 4'-substituted nucleotides
US5519134A (en)1994-01-111996-05-21Isis Pharmaceuticals, Inc.Pyrrolidine-containing monomers and oligomers
US5596091A (en)1994-03-181997-01-21The Regents Of The University Of CaliforniaAntisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en)1994-03-291997-05-06Ribozyme Pharmaceuticals, Inc.2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)1994-03-311997-04-29Amgen Inc.Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6054299A (en)1994-04-292000-04-25Conrad; Charles A.Stem-loop cloning vector and method
US5525711A (en)1994-05-181996-06-11The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesPteridine nucleotide analogs as fluorescent DNA probes
US5543152A (en)1994-06-201996-08-06Inex Pharmaceuticals CorporationSphingosomes for enhanced drug delivery
US5597696A (en)1994-07-181997-01-28Becton Dickinson And CompanyCovalent cyanine dye oligonucleotide conjugates
US5597909A (en)1994-08-251997-01-28Chiron CorporationPolynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en)1994-08-251996-12-03Chiron CorporationN-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5820873A (en)1994-09-301998-10-13The University Of British ColumbiaPolyethylene glycol modified ceramide lipids and liposome uses thereof
WO1996033761A1 (en)1995-04-281996-10-31Medtronic, Inc.Intraparenchymal infusion catheter system
US20030027216A1 (en)2001-07-022003-02-06Kiernan Urban A.Analysis of proteins from biological fluids using mass spectrometric immunoassay
US5976567A (en)1995-06-071999-11-02Inex Pharmaceuticals Corp.Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en)1995-06-071999-11-09Inex Pharmaceuticals Corp.Methods for encapsulating plasmids in lipid bilayers
US5756122A (en)1995-06-071998-05-26Georgetown UniversityLiposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US7422902B1 (en)1995-06-072008-09-09The University Of British ColumbiaLipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU705644B2 (en)1995-08-011999-05-27Novartis AgLiposomal oligonucleotide compositions
US5858397A (en)1995-10-111999-01-12University Of British ColumbiaLiposomal formulations of mitoxantrone
US5735814A (en)1996-04-301998-04-07Medtronic, Inc.Techniques of treating neurodegenerative disorders by brain infusion
WO1999001579A1 (en)1997-07-011999-01-14Isis Pharmaceuticals, Inc.Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6506559B1 (en)1997-12-232003-01-14Carnegie Institute Of WashingtonGenetic inhibition by double-stranded RNA
NZ507093A (en)1998-04-082003-08-29Commw Scient Ind Res OrgMethods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AR020078A1 (en)1998-05-262002-04-10Syngenta Participations Ag METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
WO2000003683A2 (en)1998-07-202000-01-27Inex Pharmaceuticals CorporationLiposomal encapsulated nucleic acid-complexes
AU6430599A (en)1998-10-092000-05-01Cytogenix, Inc.Enzymatic synthesis of ssdna
MXPA01003643A (en)1998-10-092003-07-21Ingene IncPRODUCTION OF ssDNA IN VIVO.
DE19956568A1 (en)1999-01-302000-08-17Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
EP1156812A4 (en)1999-02-232004-09-29Isis Pharmaceuticals IncMultiparticulate formulation
DE10100586C1 (en)2001-01-092002-04-11Ribopharma AgInhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
AU2001247951A1 (en)*2000-02-072001-08-14Roche Diagnostics CorporationNovel cationic amphiphiles
WO2002081628A2 (en)*2001-04-052002-10-17Ribozyme Pharmaceuticals, IncorporatedModulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20030072794A1 (en)*2000-06-092003-04-17Teni BoulikasEncapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
CA2429814C (en)*2000-12-012014-02-18Thomas TuschlRna interference mediating small rna molecules
WO2002059621A2 (en)2001-01-242002-08-01Bayer CorporationRegulation of transthyretin to treat obesity
US20030170891A1 (en)2001-06-062003-09-11Mcswiggen James A.RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7514099B2 (en)*2005-02-142009-04-07Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2003001182A2 (en)2001-06-212003-01-03The Cleveland Clinic FoundationHomocysteinylated transthyretin
US20030191056A1 (en)2002-04-042003-10-09Kenneth WalkerUse of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP2258847B2 (en)2002-08-052020-07-01Silence Therapeutics GmbHFuther novel forms of interfering RNA molecules
US7923547B2 (en)*2002-09-052011-04-12Sirna Therapeutics, Inc.RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040119010A1 (en)2002-11-012004-06-24The Regents Of The University Of ColoradoQuantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US9228186B2 (en)2002-11-142016-01-05Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
EP2305812A3 (en)2002-11-142012-06-06Dharmacon, Inc.Fuctional and hyperfunctional sirna
US7250496B2 (en)2002-11-142007-07-31Rosetta Genomics Ltd.Bioinformatically detectable group of novel regulatory genes and uses thereof
DE10302421A1 (en)2003-01-212004-07-29Ribopharma AgNew double-stranded interfering RNA, useful for inhibiting hepatitis C virus, has one strand linked to a lipophilic group to improve activity and eliminate the need for transfection auxiliaries
AU2004220556B2 (en)2003-03-072009-05-07Alnylam Pharmaceuticals, Inc.Therapeutic compositions
WO2004090108A2 (en)2003-04-032004-10-21Alnylam PharmaceuticalsIrna conjugates
EP2567693B1 (en)2003-07-162015-10-21Protiva Biotherapeutics Inc.Lipid encapsulated interfering RNA
US20050244869A1 (en)*2004-04-052005-11-03Brown-Driver Vickie LModulation of transthyretin expression
CA2568735A1 (en)2004-06-032005-12-22Isis Pharmaceuticals, Inc.Double strand compositions comprising differentially modified strands for use in gene modulation
ATE536418T1 (en)2004-06-072011-12-15Protiva Biotherapeutics Inc LIPID ENCAPSULATED INTERFERENCE RNA
US7745651B2 (en)*2004-06-072010-06-29Protiva Biotherapeutics, Inc.Cationic lipids and methods of use
US7838561B2 (en)*2004-06-142010-11-23Wisconsin Alumni Research FoundationMethod for preventing or treating cardiac hypertrophy
ES2246715B1 (en)*2004-08-042007-05-01Consejo Superior Investig. Cientificas ANIMAL MODEL OF NEURODEGENERATIVE DISEASES, PROCEDURE OF OBTAINING AND APPLICATIONS.
CN101189343B (en)*2004-08-232011-11-16阿尔尼拉姆药物公司Multiple rna polymerase iii promoter expression constructs
AU2005314039B2 (en)2004-12-082008-01-31Revision Therapeutics, Inc.Methods, assays and compositions for treating retinol-related diseases
DK1866414T3 (en)2005-03-312012-04-23Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
US7915230B2 (en)*2005-05-172011-03-29Molecular Transfer, Inc.Reagents for transfection of eukaryotic cells
WO2007008652A2 (en)*2005-07-082007-01-18The University Of North Carolina At Chapel HillMethods and compositions directed to dj-1 as regulator of the anti-oxidant transcription factor nrf2
JP5639338B2 (en)2005-07-272014-12-10プロチバ バイオセラピューティクス インコーポレイティッド Liposome production system and production method
JP5336853B2 (en)2005-11-022013-11-06プロチバ バイオセラピューティクス インコーポレイティッド Modified siRNA molecules and methods of use thereof
KR101362681B1 (en)2006-03-312014-02-13알닐람 파마슈티칼스 인코포레이티드Compositions and methods for inhibiting expression of Eg5 gene
US8598333B2 (en)2006-05-262013-12-03Alnylam Pharmaceuticals, Inc.SiRNA silencing of genes expressed in cancer
CA2927045A1 (en)2006-10-032008-04-10Muthiah ManoharanLipid containing formulations
GB0704764D0 (en)2007-03-122007-04-18Electrophoretics LtdIsobarically labelled reagents and methods of their use
US20110046206A1 (en)2007-06-222011-02-24Isis Pharmaceuticals, Inc.Double strand compositions comprising differentially modified strands for use in gene modulation
JP5519523B2 (en)2007-12-042014-06-11アルニラム ファーマスーティカルズ インコーポレイテッド Carbohydrate conjugates as oligonucleotide delivery agents
JP5697988B2 (en)*2007-12-272015-04-08プロチバ バイオセラピューティクス インコーポレイティッド Method for silencing polo-like kinase expression using interfering RNA
JP5749494B2 (en)2008-01-022015-07-15テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
CA2713379A1 (en)2008-01-312009-11-05Alnylam Pharmaceuticals, Inc.Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2009100390A2 (en)2008-02-082009-08-13Mayo Foundation For Medical Education And ResearchClassifying amyloidosis
NZ588583A (en)2008-04-152012-08-31Protiva Biotherapeutics IncNovel lipid formulations for nucleic acid delivery
TWI455944B (en)2008-07-012014-10-11Daiichi Sankyo Co LtdDouble-stranded polynucleotides
EP2323667A4 (en)2008-08-072012-07-25Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
PL2350043T3 (en)*2008-10-092014-09-30Tekmira Pharmaceuticals CorpImproved amino lipids and methods for the delivery of nucleic acids
ES2656516T3 (en)2008-10-202018-02-27Alnylam Pharmaceuticals, Inc. Compositions and methods to inhibit the expression of transthyretin
CN104910025B (en)2008-11-072019-07-16麻省理工学院Alkamine lipid and its purposes
CN105709229B (en)2008-11-102020-07-28阿布特斯生物制药公司 Novel lipids and compositions for delivery of therapeutic agents
US9493774B2 (en)2009-01-052016-11-15Rxi Pharmaceuticals CorporationInhibition of PCSK9 through RNAi
AU2010208035B2 (en)2009-01-292016-06-23Arbutus Biopharma CorporationImproved lipid formulation for the delivery of nucleic acids
KR20210031549A (en)2009-05-052021-03-19알닐람 파마슈티칼스 인코포레이티드Lipid compositions
KR102374518B1 (en)*2009-06-102022-03-16알닐람 파마슈티칼스 인코포레이티드Improved lipid formulation
WO2010148013A2 (en)2009-06-152010-12-23Alnylam Pharmaceuticals, Inc.Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en)2009-06-152015-06-09Tekmira Pharmaceuticals CorporationMethods for increasing efficacy of lipid formulated siRNA
US9101643B2 (en)2009-11-032015-08-11Alnylam Pharmaceuticals, Inc.Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
CA2792291A1 (en)2010-03-292011-10-06Kumamoto UniversitySirna therapy for transthyretin (ttr) related ocular amyloidosis
SI2563920T1 (en)2010-04-292017-05-31Ionis Pharmaceuticals, Inc.Modulation of transthyretin expression
AU2011302152B2 (en)2010-09-152015-06-11Alnylam Pharmaceuticals, Inc.Modified iRNA agents
EP3766975A1 (en)2010-10-292021-01-20Sirna Therapeutics, Inc.Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9339513B2 (en)2010-11-092016-05-17Alnylam Pharmaceuticals, Inc.Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2012177906A1 (en)2011-06-212012-12-27Alnylam Pharmaceuticals, Inc.Assays and methods for determining activity of a therapeutic agent in a subject
EP2780454A2 (en)2011-11-182014-09-24Alnylam Pharmaceuticals, Inc.Modified rnai agents
SMT202000308T1 (en)2011-11-182020-07-08Alnylam Pharmaceuticals IncRnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
CA2879683C (en)2012-08-032023-02-14Alnylam Pharmaceuticals, Inc.Modified rnai agents
AR097738A1 (en)2013-09-232016-04-13Alnylam Pharmaceuticals Inc METHODS TO TREAT OR PREVENT DISEASES ASSOCIATED WITH TRANSTIRETINE (TTR)
AU2014360314B2 (en)2013-12-062018-04-26Dicerna Pharmaceuticals, Inc.Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
KR102005337B1 (en)*2014-01-092019-07-30에스케이하이닉스 주식회사Voltage converter
IL316808A (en)2014-08-202025-01-01Alnylam Pharmaceuticals IncModified double-stranded rna agents and uses thereof
HRP20221055T1 (en)2014-08-292022-12-23Alnylam Pharmaceuticals, Inc.Patisiran for use in treating transthyretin mediated amyloidosis
DK3329002T3 (en)2015-07-312021-01-11Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS FOR USING IT FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES
TWI865997B (en)2016-12-162024-12-11美商阿尼拉製藥公司METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
AU2018336806B2 (en)2017-09-192025-04-10Alnylam Pharmaceuticals, Inc.Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
US10799808B2 (en)2018-09-132020-10-13Nina DavisInteractive storytelling kit
AU2019350765A1 (en)2018-09-282021-05-27Alnylam Pharmaceuticals, Inc.Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
WO2021041884A1 (en)2019-08-302021-03-04Alnylam Pharmaceuticals, Inc.Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
EP4055165A1 (en)2019-11-062022-09-14Alnylam Pharmaceuticals, Inc.Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021178778A1 (en)2020-03-062021-09-10Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of transthyretin (ttr)
EP4334448A1 (en)2021-05-032024-03-13Alnylam Pharmaceuticals, Inc.Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
EP4351541A2 (en)2021-06-082024-04-17Alnylam Pharmaceuticals, Inc.Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
CN117795074A (en)2021-08-032024-03-29阿尔尼拉姆医药品有限公司 Transthyretin (TTR) iRNA compositions and methods of use

Also Published As

Publication numberPublication date
PT2937418T (en)2018-01-23
SI2937418T1 (en)2018-02-28
CN103937793B (en)2017-08-11
IL310600A (en)2024-04-01
US20140194493A1 (en)2014-07-10
EA029762B1 (en)2018-05-31
KR102354558B1 (en)2022-01-25
HK1216652A1 (en)2016-11-25
MX344354B (en)2016-12-14
NO2019004I1 (en)2019-01-29
AU2009307677C1 (en)2022-09-22
NZ602404A (en)2014-04-30
JP2018171072A (en)2018-11-08
IL281434B1 (en)2023-05-01
LUC00098I2 (en)2019-12-24
EA036772B1 (en)2020-12-18
JP2024116226A (en)2024-08-27
IL302142A (en)2023-06-01
US20170321213A1 (en)2017-11-09
CA3018487A1 (en)2010-04-29
WO2010048228A3 (en)2010-09-16
SG10201809460SA (en)2018-11-29
US8741866B2 (en)2014-06-03
MX360460B (en)2018-11-05
EA020312B1 (en)2014-10-30
KR102578331B1 (en)2023-09-15
US20200283766A1 (en)2020-09-10
KR20150007359A (en)2015-01-20
JP7500658B2 (en)2024-06-17
EP2344639B1 (en)2015-04-22
CA2739895C (en)2018-09-25
US20230257740A1 (en)2023-08-17
JP2019205442A (en)2019-12-05
US20190309293A1 (en)2019-10-10
JP5791505B2 (en)2015-10-07
US20100120893A1 (en)2010-05-13
EP2344639A2 (en)2011-07-20
AU2009307677A1 (en)2010-04-29
NL300965I2 (en)2020-07-28
EA201400170A1 (en)2015-03-31
IL243178A0 (en)2016-02-29
EP3354733B1 (en)2020-12-09
IL243178B (en)2021-03-25
US20120225927A1 (en)2012-09-06
MX2018013398A (en)2023-01-05
KR20190116553A (en)2019-10-14
KR101624869B1 (en)2016-05-30
NZ797298A (en)2024-08-30
US8168775B2 (en)2012-05-01
ZA201102876B (en)2015-06-24
IL212428A0 (en)2011-06-30
CY2019005I1 (en)2019-11-27
ES2656516T3 (en)2018-02-27
NO2937418T3 (en)2018-03-17
HUS1900004I1 (en)2019-03-28
PL2937418T3 (en)2018-04-30
NZ592867A (en)2013-05-31
PL2344639T3 (en)2015-10-30
HK1156348A1 (en)2012-06-08
US20160264963A1 (en)2016-09-15
EP2937418A1 (en)2015-10-28
KR102031027B1 (en)2019-10-14
SMT201800027T1 (en)2018-03-08
CY1116944T1 (en)2017-04-05
CN106834291B (en)2020-09-29
LT2937418T (en)2018-02-12
ES2543004T3 (en)2015-08-13
KR20160079921A (en)2016-07-06
EP2937418B1 (en)2017-10-18
IL281434A (en)2021-04-29
WO2010048228A2 (en)2010-04-29
MX2011004268A (en)2011-06-01
EA201170591A1 (en)2011-12-30
HRP20150796T1 (en)2015-09-11
CY2019005I2 (en)2019-11-27
DK2344639T3 (en)2015-07-27
LUC00098I1 (en)2019-01-31
KR101635436B1 (en)2016-07-01
LTC2937418I2 (en)2019-12-27
CN102186978A (en)2011-09-14
US9234196B2 (en)2016-01-12
IL302142B1 (en)2024-03-01
HUE037875T2 (en)2018-09-28
CN103937793A (en)2014-07-23
KR20180017245A (en)2018-02-20
NL300965I1 (en)2019-02-06
CY1120174T1 (en)2018-12-12
CN102186978B (en)2014-03-12
AU2009307677B2 (en)2015-07-30
EP3354733A1 (en)2018-08-01
JP2012506254A (en)2012-03-15
PT2344639E (en)2015-09-07
CN106834291A (en)2017-06-13
JP2015062420A (en)2015-04-09
JP6371446B2 (en)2018-08-08
KR20110073592A (en)2011-06-29
US12227744B2 (en)2025-02-18
LTPA2019501I1 (en)2019-02-25
JP2022160408A (en)2022-10-19
IL281434B2 (en)2023-09-01
DK2937418T3 (en)2018-01-22
SG10201912276XA (en)2020-02-27
SI2344639T1 (en)2015-09-30
HRP20180093T1 (en)2018-02-23
KR20220012422A (en)2022-02-03
HUE026604T2 (en)2016-06-28
BRPI0919732A2 (en)2015-12-08
CA2739895A1 (en)2010-04-29
JP2018007666A (en)2018-01-18
HK1258859A1 (en)2019-11-22
EA201792626A1 (en)2018-08-31
JP6553780B2 (en)2019-07-31
EP3848461A1 (en)2021-07-14
IL302142B2 (en)2024-07-01
US10240152B2 (en)2019-03-26
SMT201500176B (en)2015-09-07
CA3222620A1 (en)2010-04-29

Similar Documents

PublicationPublication DateTitle
IL281434B1 (en)Compositions and methods for inhabiting expression of transthyretin
EP2334185A4 (en)Compositions and methods of using (r)-pramipexole
EG26471A (en)Compositions and methods for inhibiting the agglomeration of hydrates
EP2294156A4 (en)Methods for prevention and reduction of scale formation
EP2318395A4 (en)Inhibitors of iap
ZA201004914B (en)Compositions and methods of detecting tiabs
ZA201006719B (en)Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PL2512502T3 (en)Methods and compositions for liquidation of tumors
ZA201103424B (en)Compositions and methods for inhibiting expression of factor vii genes
IL208403A0 (en)Compositions and use of epas1 inhibitors
EP2231665A4 (en)Novel compositions and methods of use
IL216993A0 (en)Compositions and methods for treatment of multiple sclerosis
EP2507373A4 (en)Compositions and methods for inhibition of vegf
PL2179657T3 (en)Gas-effusing compositions and methods of making same
GB0812890D0 (en)Compositions and methods of making compositions
ZA201004765B (en)Inhibitors of iap
ZA201102207B (en)Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en)Apoaequorin-containing compositions and methods of using same
PL2328402T3 (en)Methods and compositions for increasing storage-life of fruit
EP2381950A4 (en)Compositions and methods of use
IL215486A0 (en)Compositions of cholinesterase inhibitors
GB201011469D0 (en)Method of and composition for combating undesired microorganisms

[8]ページ先頭

©2009-2025 Movatter.jp